Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter results were rather uneventful, with the company already announcing ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound ... He said he would “bet dollars to doughnuts” that they were on weight-loss medication. Some cardiologists are ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don't just curb their desire to eat; for some, they also lead them to drink ...